Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.-Reference-Cited by-同舟云学术

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

Published:2010-05-20 Issue:15_suppl Volume:28 Page:7507-7507
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Perol M.,Chouaid C.,Milleron B. J.,Gervais R.,Barlesi F.,Westeel V.,Crequit J.,Lena H.,Vergnenegre A.,Pérol D.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2010.28.15_suppl.7507

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trial designs for evaluating and exploiting cancer evolution;Cancer Treatment Reviews;2023-07

2. State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer;Frontiers in Oncology;2022-08-01

3. Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the Surveillance, Epidemiology and End Results (SEER) database;Translational Cancer Research;2021-12

4. Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial;Annals of Translational Medicine;2021-02

5. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study;The Lancet Oncology;2016-12